

## ENSAYOS CLÍNICOS MELANOMA, TUMORES CUTÁNEOS, SNC, PULMÓN, SARCOMA Y CABEZA CUELLO.

### - MELANOMA

#### **R3767-ONC-2055**

*A phase 3 trial of fianlimab (anti-lag-3) and cemiplimab versus pembrolizumab in the adjuvant setting in patients with completely resected high-risk melanoma*

<https://classic.clinicaltrials.gov/ct2/results?cond=&term=R3767-ONC-2055&cntry=&state=&city=&dist=>

#### **R3767-ONC-2011**

*Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma*

<https://clinicaltrials.gov/search?term=R3767-ONC-2011>

#### **INCB99280-212**

*A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma. The study consists of 2 parts. In Part 1, participants with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC will be randomized 1:1:1 to INCB099280 Dose 1, Dose 2, or Dose 3. In Part 2, one dose level identified from Part 1 will be expanded to enroll additional participants with metastatic cSCC and locally advanced cSCC*

<https://classic.clinicaltrials.gov/ct2/show/NCT05888844?term=INCB99280-212&draw=2&rank=1>

#### **IMCGP100-203**

*Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)*

<https://www.clinicaltrials.gov/search?limit=10&term=IMCGP100-203>

#### **ALKS 4230-006 (ARTISTRY-6)**

*Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy*

<https://clinicaltrials.gov/ct2/show/NCT04830124>

### **IOV-MEL-301 (TILVANCE-301)**

*Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.*

<https://clinicaltrials.gov/study/NCT05727904?term=IOV-MEL-301&cond=melanoma&rank=2#locations>

### **ERAS-254-02 (SEACRAFT-2)**

*A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)*

<https://clinicaltrials.gov/study/NCT06346067?term=ERAS-254-02%20&rank=1>

### **PRISM-MEL-301**

*IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)*

<https://clinicaltrials.gov/study/NCT06112314?term=PRISM-MEL-301&rank=1>

### **- SISTEMA NERVIOSO CENTRAL**

### **APL-101-01 (SPARTA, APOLLOMICS)**

*Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors*

<https://classic.clinicaltrials.gov/ct2/results?cond=&term=APL-101-01&cntry=&state=&city=&dist=>

### **- PULMÓN**

### **DS1062-A-U304 (Tropion-Lung08)**

*A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)*

<https://clinicaltrials.gov/ct2/show/NCT05215340>

### **APL-101-01 (SPARTA)**

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

<https://www.clinicaltrials.gov/ct2/show/NCT03175224?term=APL-101-01&draw=2&rank=1>

### **PALOMA-2 (61186372NSC2002)**

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

<https://clinicaltrials.gov/ct2/show/NCT05498428>

### **PM1183-C-008-21(LAGOON)**

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line

<https://clinicaltrials.gov/ct2/show/NCT05153239?term=PM1183-C-008-21&draw=2&rank=1>

### **849-017 (Krystal-17)**

Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS  $\geq$  1%, TPS <50% and KRAS G12C mutation

<https://clinicaltrials.gov/study/NCT05609578?term=MIRATI%20849-017%20&rank=1>

### **DS1062-A-U303 (Tropion-Lung07)**

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

<https://www.clinicaltrials.gov/study/NCT05555732?term=DS1062-A-U303%20&rank=1>

### **VS-6766-203 (RAMP203)**

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP203)

<https://clinicaltrials.gov/study/NCT05074810?term=VS-6766-203&rank=1h>

### **D516AC00003 (NEOLA)**

*A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)*

<https://clinicaltrials.gov/study/NCT06194448?term=D516AC00003&cond=Lung%20Cancer&rank=1>

### **SGNBGA-002**

*A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer with or without actionable genomic alterations*

<https://www.clinicaltrials.gov/search?term=SGNB6A-002>

### **HLX10-020-SCLC302**

*A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer*

<https://www.clinicaltrials.gov/study/NCT05353257?term=HLX10-020&rank=1>

### **D9106C00002 (MDT-BRIDGE)**

*A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)*

<https://clinicaltrials.gov/study/NCT05925530?term=D9106C00002&cond=Lung%20Cancer&rank=1>

### **20210104 (FORTITUDE-301)**

*A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)*

<https://clinicaltrials.gov/study/NCT05325866?term=20210104&cond=Lung%20Cancer&rank=1>

### **GETNE-T2217 (LEVEL) – NEUROENDOCRINOS (PULMÓN Y TIMO)**

*Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL)*

<https://clinicaltrials.gov/study/NCT05918302?term=GETNE-T2217&rank=1>

### **R2810-ONC-2045**

*A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)*

<https://clinicaltrials.gov/search?term=R2810-ONC-2045%20&limit=10>

### **MK2870-004**

*A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations*

<https://clinicaltrials.gov/study/NCT06074588?term=2870%20004&limit=10&checkSpell=&rank=1>

### **BO45217 (KRASCENDO-1)**

*A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)*

<https://clinicaltrials.gov/study/NCT06497556?term=BO45217&rank=1>

### **BAY 2927088 (SOHO-2)**

*A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)*

<https://clinicaltrials.gov/study/NCT06452277?term=BAY%202927088%20&rank=1>

### **213823 (GALAXIES LUNG 301)**

*A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)*

<https://clinicaltrials.gov/study/NCT06472076?term=213823&rank=1>

### **KRYSTAL-21 (849-021)**

*Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)*

<https://clinicaltrials.gov/search?term=849-021>

- SARCOMAS

**GEIS-75 (Synergias)**

*"Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas"*

<https://www.clinicaltrials.gov/ct2/show/NCT05131386?term=qeis-75&draw=2&rank=1>

**GEIS-35 (rEECur)**

*"International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma"*

[No link available](#)

**FaR-RMS**

*"Treatment of Recurrent and Primary Refractory Ewing Sarcoma" FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma*

<https://clinicaltrials.gov/ct2/show/NCT04625907?term=faR-RMS&draw=2&rank=1>

**PH-L19TNFDOX2-03/16 FIBROSARC**

*"A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma"*

<https://www.clinicaltrials.gov/ct2/results?cond=&term=PH-L19TNFDOX2-03%2F16&cntry=&state=&city=&dist=>

**EORTC 1809-STRASS 2**

*A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)*

[No link available](#)

**PM1183-C-010-22 (SALUDO)**

*Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma*

<https://classic.clinicaltrials.gov/>

**CLIN-60000-461**

*Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma (CabOSTar)*

<https://clinicaltrials.gov/study/NCT06341712?term=CLIN-60000-461&rank=1>

**DCC-2618-03-003 (INSIGH)**

*A Study of Ripretinib Vs Sunitinib in Patients with Advanced GIST with Specific KIT Exon Mutations Who Were Previously Treated with Imatinib (INSIGHT)*

<https://clinicaltrials.gov/study/NCT05734105?term=DCC-2618-03-003&rank=1>

**REECUR**

*An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. Ifosfamide high dosis + lenvatinib*